Ablator (HTA) system, an endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia. Neuromodulation Within its Neuromodulation business, the company markets the Precision and Precision Spectra Spinal Cord Stimulator (SCS) systems, used for the management of chronic pain. This system delivers pain management by applying an electrical signal to mask pain signals traveling from the spinal cord to the brain. The company’s product offerings include the Infinion 16 Percutaneous Lead, and its Linear 3-4 and Linear 3-6 Percutaneous Leads, which are designed to provide physicians with more treatment options for their chronic pain patients. The company received CE Mark approval for the Precision Spectra SCS System during 2012 and the company commenced its U.S. commercial launch of the device during 2013 following FDA approval. The Precision Spectra SCS System is a SCS system with 32 contacts and 32 dedicated power sources and is designed to provide improved pain relief to a range of patients who suffer from chronic pain. In 2012, the company received CE Mark approval for the use of its Vercise Deep Brain Stimulation (DBS) System for the treatment of Parkinson's disease in Europe. In 2013, the company announced CE Mark approval for its Vercise DBS System for the treatment of intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions. Business Strategy The company’s strategy includes the following elements: strengthening execution to grow share; expanding into high growth adjacencies; driving global expansion; funding the journey to fuel growth; and developing key capabilities. Research and Development The company expended $861 million on research and development in 2013. Sales and Marketing During 2013, the company marketed its products to approximately 13,000 hospitals, clinics, outpatient facilities and medical offices in approximately 100 countries worldwide. The company also has a network of distributors and dealers who offer its products in certain countries and markets. Seasonality Customer purchases have been lighter in the third quarter of the year, as compared to other quarters. There is a lower demand during summer months in the northern hemisphere, particularly in European countries. Proprietary Rights As of December 31, 2013, the company held approximately 16,000 patents, and had approximately 7,200 patent applications pending worldwide that cover various aspects of its technology. In addition, the company holds exclusive and non-exclusive licenses to a variety of third-party technologies covered by patents and patent applications. Significant Events In August 2014, Boston Scientific Corporation and ASAHI INTECC have formalized plans to develop a new, differentiated fractional flow reserve (FFR) wire. The joint project focuses on creating a device intended to improve handling compared to existing FFR wires. Competition The company’s primary competitors include Abbott Laboratories; Medtronic, Inc.; St. Jude Medical, Inc.; and Cook Medical. History Boston Scientific Corporation was founded in 1979.
boston scientific corp
(BSX:New York Consolidated)
One Boston Scientific Place
Natick, MA 01760
|No competitor information is available for BSX.|
|View Industry Companies|
|No financial data is available for BSX.|
Sponsored Financial Commentaries
To contact BOSTON SCIENTIFIC CORP, please visit www.bostonscientific.com. Company data is provided by Capital IQ. Please use this form to report any data issues.